FDA Brief

Warning letters Food

FDA warning letter to

Half Hill Farm Inc.

LowIssued Mar 6Posted Apr 14Human Foods Program

FDA cited Half Hill Farm's mushroom extracts as unapproved new drugs over website disease-treatment claims.

What happened

FDA inspected the facility at 110 W. High St., Woodbury, TN, from 05/28/25 to 05/30/25 and reviewed labeling collected during the inspection and the website www.halfhillfarm.com in February 2026. FDA found that the website cited publications linking Turkey Tail, Chaga, and Red Reishi mushroom extracts to cancer, herpes, and other diseases, which FDA treated as evidence the products are intended as drugs. FDA also found the products misbranded because they lack adequate directions for use.

What FDA found

  1. FDA said citing publications can be a disease claim when the citation refers to a disease use and implies treatment or prevention.

    21 CFR 101.93(g)(2)(iv)(C)
  2. FDA said website citations to cancer and other disease research show the mushroom extracts are intended to treat disease, making them new drugs without FDA approval.

    sections 201(g)(1)(B), 301(d), and 505(a) of the Act [21 U.S.C. 321(g)(1)(B), 331(d), 355(a)]
  3. FDA said the products are not generally recognized as safe and effective for the cited disease uses, so they meet the definition of new drugs.

    section 201(p) of the Act [21 U.S.C. 321(p)]
  4. FDA said the products are misbranded because they do not bear adequate directions for a layperson to use them safely for their intended disease uses.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  5. FDA said introducing or delivering these misbranded drugs into interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]
  6. FDA said the company's June 13, 2025 response did not include documentation that the label changes it described had been made.

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt of the letter of the specific steps taken to address the violations, including an explanation and documentation to prevent recurrence. If corrective actions cannot be completed in that time, the company must state the reason and the time within which it will do so.

Who should pay attention

  • dietary supplement brands that cite research on product websites
  • mushroom extract sellers and distributors
  • retailers that carry supplements with disease-treatment claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk